Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) are widely used in the management of type 2 diabetes due to their glucose-lowering effects and favorable safety profile. However, emerging evidence suggests that GLP-1 RAs may also have a dual role in prostate cancer, with both beneficial and potentially harmful effects. This article provides an overview of the current understanding of the dual role of GLP-1 RAs in prostate cancer, highlighting their potential as a therapeutic target in oncology.
HTML PDFShare this article
Reports in Thyroid Research received 2 citations as per Google Scholar report
